Purpose: To compare characteristics of laser treatment for high-risk type 1 retinopathy of prematurity (ROP) in eyes treated with primary laser versus laser after an initial treatment with intravitreal anti-vascular endothelial growth factor (anti-VEGF).
Methods: The medical records of consecutive patients at a single academic institution treated for type 1 ROP before 36 weeks' postmenstrual age with primary laser versus laser after initial treatment with anti-VEGF were reviewed retrospectively. Outcome measures were laser spot number, mean laser power, total laser energy (Joules), and retinal vascularization to the nasal ora at time of laser treatment.
Results: Compared with the 46 eyes treated with primary laser, the 46 eyes treated with laser after anti-VEGF required fewer spots (mean, 775 vs 1418 [P < 0.01]), less power (182 vs 223 mW [P < 0.01]), and less total energy (27 vs 61 Joules [P < 0.01]), and showed greater vascularization to the nasal ora at the time of laser treatment (47.8% vs 6.5% [P < 0.01]).
Conclusions: In our study cohort, laser after initial anti-VEGF treatment may have allowed for greater retinal vascularization and been less destructive than primary laser for high-risk type 1 ROP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaapos.2022.05.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Technological innovation of HoLEP: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
World J Urol
January 2025
Department of Urology, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China.
Purpose: The purpose of this study was to investigate the efficacy of Transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Technology in the treatment of benign prostatic hyperplasia (BPH), with a focus on preserving sexual function postoperatively.
Methods: Conducted as a multicenter, prospective, single-blind randomized controlled trial, this study enrolled sexually active male patients with BPH. Participants were randomized into three groups: standard HoLEP (Group A), single-n technology (Group B), and innovative double-n technology (Group C), which emphasizes the preservation of the urethral mucosa and nearby structures.
Efficacy of laser therapy on primary burning mouth syndrome: a systematic review.
J Oral Facial Pain Headache
March 2024
Department of Dental Medicine, Fattouma Bourguiba University Hospital of Monastir, 5000 Monastir, Tunisia.
The objective of this study was to perform a systematic review of the literature to determine the overall efficacy of low-level laser therapy (LLLT) in managing burning mouth syndrome (BMS). A literature search was conducted through PubMed, Scopus, Web of Sciences, and Cochrane Central Register of Controlled Trials from their inception up to 28 March 2023. The search terms were defined by combining (Mesh Terms OR Key Words) from "Burning mouth syndrome" AND (Mesh Terms OR Key Words) from "Laser therapy".
View Article and Find Full Text PDFLaser-Driven Dissection Achieves Earlier Continence Recovery Than Blunt Dissection During Holmium Laser Enucleation of the Prostate.
Low Urin Tract Symptoms
January 2025
Farwaniya Hospital, Farwaniya, Kuwait.
Objectives: During holmium laser enucleation of the prostate (HOLEP), blunt dissection (BD) by pushing the tip of the scope may exert mechanical force on the sphincter that could be avoided by adopting laser dissection (LD). This study evaluates the continence recovery in consecutive patients who underwent BD and LD.
Methods: A prospective cohort of patients who underwent LD was compared with a retrospective control that underwent BD.
Triple-action cancer therapy using laser-activated NO-releasing metallomicellar nanophotosensitizer for pyroptosis-driven immune reprogramming.
J Control Release
January 2025
Department of Biomedical Sciences and BioMedical Sciences Graduate Program (BMSGP), Chonnam National University Medical School, Gwangju 61469, Republic of Korea; DR Cure Inc., Hwasun 58128, Republic of Korea. Electronic address:
Cancer photoimmunotherapy represents an intelligent and highly efficient therapeutic approach that harnesses the photothermal effect to precisely target and ablate tumor tissues, while simultaneously modulating the immune system to achieve tumor elimination. The integration of multifunctional therapeutic modalities for combined photoimmunotherapy requires advanced drug delivery systems. However, the design of a single nanoagent capable of serving as a multifunctional nanophotosensitizer remains a significant challenge.
View Article and Find Full Text PDFEfficacy and Safety of UVA1 Phototherapy Adjunct Treatment for Acute Cutaneous Inflammations and Neuralgia of Herpes Zoster: A Prospective, Randomized, Open-Label, Blinded End-Point Study.
Photobiomodul Photomed Laser Surg
January 2025
Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, China.
Previous case reports hint ultraviolet A1 (UVA1) phototherapy as a novel adjunct treatment for acute cutaneous inflammations and neuralgia of herpes zoster, but its clinical effectiveness and safety in this condition are not yet proven by clinical trials. To determine the efficacy and safety of UVA1 phototherapy as an adjunct treatment for acute inflammation and neuralgia in herpes zoster. A total of 60 patients with moderate-to-severe acute herpes zoster were randomly divided into two parallel groups.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!